Review anchor
HCT-116
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
HCT-116
CHEMBL394
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HCT-116 as ChEMBL target CHEMBL394. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL394
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why HCT-116 matters
HCT-116 is reviewed as HCT-116; the current evidence base includes 112 approved drugs, 75438 compounds, and 13633 assays, with lead potency reaching pChEMBL 11.0.
Protein context
HCT-116
HCT-116
Review this target as HCT-116.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 112 approved drugs, 75438 compounds, and 13633 assays for this target. The dominant activity type is IC50. CHEMBL187738 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL187738 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
112 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why HCT-116 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
75438
Total Compounds
13633
Total Assays
112
Approved Drugs
IC50: 27922.0, KI: 1.0, EC50: 1201.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL187738
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL846
|
11.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL4205723
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL492573
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL441018
|
10.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FRUQUINTINIB
CHEMBL4303214
|
2023 |
|
|
ARTESUNATE
CHEMBL361497
|
2020 |
|
|
LONAFARNIB
CHEMBL298734
|
2020 |
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
TIRBANIBULIN
CHEMBL571546
|
2020 |
|
|
TALAZOPARIB
CHEMBL3137320
|
2018 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
COPANLISIB
CHEMBL3218576
|
2017 |
|
|
NIRAPARIB
CHEMBL1094636
|
2017 |
|
|
PANOBINOSTAT
CHEMBL483254
|
2015 |
|
|
BELINOSTAT
CHEMBL408513
|
2014 |
|
|
TRAMETINIB
CHEMBL2103875
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
REGORAFENIB
CHEMBL1946170
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
CABAZITAXEL
CHEMBL1201748
|
2010 |
|
|
ROMIDEPSIN
CHEMBL343448
|
2009 |
|
|
CARFILZOMIB
CHEMBL451887
|
2009 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
LAPATINIB
CHEMBL554
|
2007 |
|
|
IXABEPILONE
CHEMBL1201752
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
TEMOPORFIN
CHEMBL500576
|
2001 |
|
|
EPIRUBICIN
CHEMBL417
|
1999 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
RALTITREXED
CHEMBL225071
|
1996 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
CLADRIBINE
CHEMBL1619
|
1993 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
PYRVINIUM
CHEMBL1201303
|
1982 |
|
|
DIGITOXIN
CHEMBL254219
|
1982 |
|
|
NICLOSAMIDE
CHEMBL1448
|
1982 |
|
|
VERAPAMIL
CHEMBL6966
|
1981 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DAUNORUBICIN
CHEMBL178
|
1979 |
|
|
CALCITRIOL
CHEMBL846
|
1978 |
|
|
DIGOXIN
CHEMBL1751
|
1975 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
VINBLASTINE SULFATE
CHEMBL378544
|
1965 |
Source Header